Our Board of Directors reflects Expanesthetics' commitment to innovation and excellence, bringing together seasoned leadership and diverse expertise. The team includes a visionary founder, a biotech leader with public biotech company experience, and accomplished professionals in finance, government, and medicine. Their combined experience guides the company in advancing its mission to transform anesthetic drug development.
The Management Team brings together a diverse blend of skills and expertise, driving the company's efforts with a unique combination of scientific innovation, quantitative rigor, and operational precision. With complementary backgrounds across clinical research, advanced analytical methods, operations, communications, and strategic advisory work, the team excels in building asset value and fostering strategic growth. Their capabilities include globally recognized expertise in anesthetic research, advanced technical proficiency in data-driven decision-making, and effective communication strategies that strengthen collaboration across diverse stakeholders.
The Expanesthetics team greets guests at the world's largest anesthesia conference.
The Scientific and Clinical Advisory Boards feature distinguished experts from academia, healthcare, and private practice, offering unparalleled insight to advance the company's mission. Members include leading researchers, clinicians, and innovators from prestigious institutions and healthcare systems, contributing expertise in anesthesiology, pain management, and related fields. Their guidance ensures the company's research aligns with clinical needs and supports transformative innovation as we seek new inhaled anesthetic drugs.
Study investigators evaluating data with Founder Mark Holman (right).
Expanesthetics has been uniquely powered directly by the market, with over 100 financially accredited anesthesiologists and other anesthesia clinicians—including CRNAs, dentists, and oral surgeons-joining forces with a handful of experienced business-building families. Together, they provided seed funding and patient follow-on Series-type funding, enabling Expanesthetics to grow from inception to a clinical trial candidate. Backing directly from end-market users demonstrates their confidence in the company's groundbreaking approach to addressing unmet needs in anesthetic drug development, as well as their belief in the clinical and financial opportunities that our success would create.
